[@hubermanlab] Mushrooms for the Mind & Immune System | Paul Stamets
Link: https://youtu.be/7mEK5wZHpto
Duration: 148 min
Transcript: Download plain text
Short Summary
Huberman interviews mycologist Paul Stamets — a 71-year-old applied mycologist from an Ohio wheat-farming family, often described as the father of modern applied mycology — about fungi, immunity, and "natural intelligence." They cover the agaricon and turkey tail mycelium trial data, H5N1 bird flu and AI-engineered bioweapon risk, psilocybin dosing and psychedelic therapy, and mycelial remediation of oil and farm runoff. Stamets argues mushrooms are "force amplifiers" for vaccine efficacy and brain health, urging listeners to follow the science.
Key Quotes
- "Bird flu has jumped to 90 mammal species, 90. And the fatality rate of H5N1, if it hits humans, is about 40 to 50%. That's going to make CO look like a minor viral pandemic." (00:00:10)
- "the greatest achievement of science this century, the acknowledgement of our ignorance." (00:04:11)
- "Those people who took a garacon on turkey tail and had the vaccine had triple the antibbody reservoirs against COVID than those individuals who just got the vaccine." (00:34:49)
- "I think psilocybin will go down as a paradigm shifting drug rediscovered that could have the most dramatic impact for the health of individuals in society of any medicine discovered in history." (01:21:01)
- "psilocybin mushrooms should be available for everybody for free because the return on investment to society as as in the many billions and billions of dollars, the receticism, the reduction of the number of people going to courts, to prisons, this is a huge paradigm shifting potential breakthrough for society." (01:32:06)
Detailed Summary
Paul Stamets on Fungi, Immunity, Psilocybin, and Mycoremediation
Episode Scope and Paul Stamets’s Background
Andrew Huberman interviews mycologist Paul Stamets about fungal biology, immune function, neuroplasticity, psychedelic therapy, and environmental remediation. The conversation combines Stamets’s own research and product-line experience with broader claims about “natural intelligence,” AI, biodiversity, and the future of medicine.
- Stamets is often described as the father of modern applied mycology and has studied what can be done with fungi since age 14, beginning by finding and identifying mushrooms.
- Born July 17, 1955, he grew up on an Ohio wheat-farming family that cultivated thousands of acres; he says he would be happy to inherit 200 acres.
- Huberman states that he has no financial relationship with Stamets’s company, Host Defense, and says he asked about specific strains, dosages, and sources for his own use and for listeners.
- Stamets’s fraternal twin brother is named North, while Stamets’s middle name is South. They competed in marathon push-ups from about age 10 and remained intensely competitive.
- As a ninth grader in Columbiana, Ohio, Stamets won a push-up contest open to students in grades 9–12, beginning with a story that returns at the close of the episode.
- Stamets’s research spans immune modulation, tissue healing and remodeling, brain plasticity, functional mushrooms, antiviral screening, psilocybin, and mycoremediation.
H5N1 and the Case for “Natural Intelligence”
The episode opens with the threat of H5N1 bird flu and the limits of artificial intelligence. Stamets argues that the more durable response to emerging pandemics may come from strengthening the body’s own “natural intelligence” rather than relying exclusively on narrowly targeted drugs or vaccines.
- Two Washington State dairy farms were reportedly under quarantine because of H5N1, and Stamets said the virus had reached about 90 mammal species, including seals, sea lions, and marmots.
- Stamets characterizes the human fatality rate for H5N1 as roughly 40–50%, which he says would make COVID-19 appear to be a comparatively minor viral pandemic.
- He warns that COVID-19 was not the last pandemic and frames factory farming, transportation density, and population concentration as factors that can accelerate viral emergence.
- His “natural intelligence” concept centers on upregulating the body’s endogenous immune system so it can generate protective antibodies and adapt more broadly to pathogens.
- Referring to a conversation with an AI expert he calls “Yra,” Stamets says AI had already discovered 99% of the discoverable data in the human experience, leaving a data deficit that natural systems could help address.
- Stamets argues that natural intelligence will ultimately exceed artificial intelligence and that the inability to explain every mechanism does not make the effects of healthy ecosystems unreal.
- He describes humans as roughly 90% bacterial and says bodies function as communities of cooperating organisms with mutual protection and cross-immunity.
- Because human bodies are semi-permeable membranes, he argues that constant cross-molecular communication occurs between external ecosystems and internal microbiomes; Huberman proposes that AI could help identify fungal mechanisms to use against human pathogens.
Fungal Evolution and the Scale of Mycelium
Fungi and animals are presented as ancient relatives whose digestive strategies diverged more than a billion years ago. Their discussion then expands from evolutionary history to the extraordinary density and ecological reach of mycelial networks.
- Fungi and animals share the superkingdom Opisthokonta: the Holozoa branch led to animals, while the Holomycota branch led to fungi.
- Stamets dates the divergence to roughly 1–1.5 billion years ago, when fungi began digesting nutrients externally while the lineage leading to animals encapsulated food and evolved internal digestion.
- A cubic inch of mycelium-rich soil can reportedly contain 1–8 miles of mycelial network, more than one million bacterial species, and more than one billion co-inhabiting organisms.
- The resulting lattice establishes a microbiome in which fungi, bacteria, plants, and other organisms exchange nutrients and chemical signals.
- Fungi produce antibiotics such as penicillin, and pathogens that affect fungi—including E. coli and Clostridium—can also affect humans.
- Mycelium can act as a prebiotic by forming alliances with beneficial bacteria that suppress pathogenic organisms, giving it a role analogous to that of beneficial microbes in the human gut.
- Stamets says marine mycology remains largely unexplored; fungal life was found in ocean-core samples more than a mile and a half down, and the oceans may contain Earth’s largest fungal reservoirs.
Mycelium as the Mushroom’s Immune System
Stamets distinguishes the rapidly decaying fruiting body from the persistent mycelial network that produced it. In his framing, the mycelium contains much of the organism’s immune and chemical complexity and is therefore the more relevant subject for immunologic and therapeutic research.
- A mushroom is essentially an aggregate of mycelium; its fruiting body lacks a strong immune system and often rots quickly.
- The mycelial network functions as the immune system of the fungal life cycle and responds to threats throughout the organism’s underground environment.
- Stamets says mycelial networks express 10–100 times more genes than the mushrooms they produce, creating what he calls an “immunological wisdom” that conventional immunology has yet to fully characterize.
- Fungi can function as miniature pharmaceutical factories by producing hundreds or thousands of molecules that are not found elsewhere in nature.
- Some fungi can grow on and break down rock and concrete, and shaggy mane mushrooms are known to push through asphalt.
- Less than 0.1% of fungal species have been tested, according to the discussion, leaving most of the kingdom’s potentially useful molecules unexplored.
Primates, Mushrooms, and the Unevidenced Brain-Expansion Hypothesis
Stamets uses family history and evolutionary examples to argue that mushroom consumption is deeply connected to primate development. Huberman pushes that argument toward a stronger claim about fetal brain expansion, but Stamets gives a notably restrained answer.
- Stamets’s older brother John, six years older, was a serious chemist headed to Yale but did not allow Paul to conduct laboratory experiments.
- Paul instead strung wire between glass insulators and made longwave radio transmissions to listen for coded messages from behind the Iron Curtain.
- John traveled to Mexico and Colombia and returned with stories about psilocybin mushrooms, describing that field as “a really interesting area” and stimulating his brother’s broader interest in fungi.
- Paul searched for psilocybin mushrooms for years without success and instead encountered edibles such as chanterelles, porcini, shaggy manes, and blewits.
- More than 20 primates—roughly 21–22 when humans are included—are said to eat mushrooms and distinguish toxic from edible species through generational knowledge without language or field guides.
- A Bolivian monkey reportedly consumes mushrooms representing more than 10–15% of its body weight over a year, while flies lay eggs in mushrooms and maggots develop inside them.
- Stamets warns that wild mushroom foraging is “Russian roulette” because some of the deadliest species are visually and gastronomically appealing; Huberman counters that ancestral humans also learned which plants and frogs were safe by experimentation.
- Huberman asks whether mushroom-derived molecules consumed by primate ancestors could have altered fetal genomes and driven brain expansion. Stamets answers “I don’t know,” while noting that better nutrition obviously helps a mother carry a child to term.
- Stamets also describes multigenerational family mushroom patches that create a literal bridge between generations when a particular mushroom is discovered and passed on.
From a One-Page Article to Project Bioshield
The account of Stamets’s antiviral career begins with a concise literature review and expands into federal biodefense testing. The chronology moves from a small shipment to Dr. Frank Panov in the 1970s to post-9/11 screening under Project Bioshield.
- In June 2001, Stamets published a one-page survey of antiviral-mushroom literature in HerbalGram, the journal of the American Botanical Council.
- In the 1970s, virologist Dr. Frank Panov asked Stamets for the gypsy mushroom, then called Cortinarius caperatus and now identified as Rozites caperata, after observing antiviral activity.
- Stamets shipped roughly 20 pounds of the mushroom by Federal Express, and Panov subsequently isolated a novel glycoprotein, RC183, that was highly active against herpes viruses.
- After 9/11, a physician connected with the Project Bioshield biodefense program contacted Stamets about weaponizable viruses such as smallpox and influenza.
- The physician gave Stamets permission to screen his fungal culture collection and conducted about 265 assays without charging the project.
- Results were reportedly strong against orthopox and influenza viruses, ranking among the top 10 of more than two million samples surveyed and representing the only natural product in that top group.
- Stamets appeared on NPR with an FDA deputy director and the head of the Bioshield program, giving the work visibility beyond the fungal research community.
Re-Testing a Two-Decade-Old Bioshield Extract
The discussion returns to the original antiviral program through a long-stored agaricon extract. This material serves as an example of Stamets’s belief that whole natural products can retain activity that would be lost if researchers isolated only one constituent.
- An agaricon extract from the 2004 Bioshield work reportedly sat in a glass gallon mason jar for 17 years and then another four years under refrigeration.
- The extract was stored in 35% ethanol, and Stamets notes that beta-glucans precipitate at 25% alcohol, so its activity could not be attributed to those polysaccharides alone.
- When retested, the roughly 20-year-old extract was described as “massively active against COVID” in the laboratory.
- Cells exposed to the virus developed plaques, died, and released new virions, but the culture reportedly healed within five days.
- The result was presented as an extension of the earlier Bioshield activity against pox, herpes, and influenza viruses.
Ganoderma, Mary Hunt, and the Search for a “Super Strain”
Ganoderma, or reishi, anchors the discussion of long-lived medicinal fungi and strain selection. Stamets’s stated goal is to repeat the kind of breakthrough associated with Mary Hunt’s penicillin-producing mold, this time against H5N1.
- Ganoderma can live for more than 100 years in old-growth forests and occurs in northern California, Washington, Oregon, British Columbia, Montana, and northern Arizona.
- It is listed on Europe’s red list of endangered species and therefore cannot legally be collected there.
- Stamets describes Ganoderma as the sole species in its genus and the sole genus in its family, with two other species recently described, while also noting that reishi-associated fungi encompass roughly 300 species.
- The first complete genome sequence for a ganoderma was published in G3: Genes|Genomes|Genetics.
- Dioscorides described Ganoderma in De Materia Medica in 65 AD as “elixirium ad longum vitam,” the elixir of long life.
- A medical foundation and university collaborators awarded $2.6 million to examine the fungus, and Stamets says he maintains 130 strains selected for potentially high production.
- The objective is to find a “Mary Hunt” strain against H5N1, analogous to Hunt’s discovery of a Penicillium chrysogenum strain that produced far more usable penicillin than earlier samples.
Developing Host Defense and Meeting the FDA’s Safety Condition
Host Defense began in 2020 after people familiar with the research asked Stamets’s team to package agaricon and turkey tail for immune support. The FDA’s concern about excessive immune stimulation shaped the formulation and the team’s reliance on its existing safety data.
- Stamets says a group that had read the team’s published work approached it during the urgency of COVID-19 and requested a host-defense product line.
- Agaricon and turkey tail were bundled using the same materials intended for the team’s nutraceutical line, alongside three papers on turkey tail.
- According to Stamets, the FDA’s first condition was that the product not overstimulate the immune system, because cytokine-storm immune overactivity can be fatal in COVID-19, Ebola, and influenza.
- The team addressed that concern using existing safety information, including the published Project Bioshield data.
- Research conducted around 2012–2019 found that growing mycelium on rice and fermenting the rice created a material distinct from either the mycelium or the fruiting body alone.
- A breast-cancer study published in the Journal of Inflammation Research found that the rice-fermented product stimulated anti-inflammatory cytokines, including interleukin-10 and interleukin-1RA, supporting immune upregulation without the overexpression the FDA wanted to avoid.
- The work was privately supported through the Crump Institute for Integrative Medicine at UC San Diego and UCLA Medical School and covered 140 participants across two studies, with vaccine-enhancement results published in BMC Immunology.
- The vaccine paper was published first, partly to manage the anticipated claim that a natural product might be presented as a vaccine replacement.
- The team deliberately preserved the complexity of whole organisms rather than reducing the products to one molecule, arguing that biological synergism may matter more than fractionation.
Vaccine and COVID Trial Outcomes
The episode presents several clinical studies of the agaricon-and-turkey-tail formulation, including vaccine coadministration and treatment of people already sick with COVID-19. The reported outcomes include reduced reactogenicity, increased antibody reserves, faster symptom resolution, and no adverse events in a comparatively large phase-one safety study.
- In double-blind, placebo-controlled studies, the placebo was the rice substrate. Participants receiving the mushroom product alongside Pfizer or Moderna mRNA vaccines showed enhanced vaccine responses and statistically significant reductions across ten commonly reported vaccine-reaction symptoms.
- Stamets said he had taken a COVID-19 vaccine approximately eight days earlier with the mushroom product and experienced no adverse effects, presenting this as a personal report rather than trial data.
- After blood from 90 participants was banked, roughly 10–12 co-authors proposed bringing the participants back six months later for repeat blood draws; Stamets credits the team rather than himself for the idea.
- The six-month analysis reportedly found that participants who took agaricon and turkey tail with the vaccine had triple the COVID antibody reserves of participants who received only the vaccine.
- Because the product was taken for only four days, Stamets interprets the result as evidence that it may raise the immune system to a higher state of readiness rather than acting as a conventional vaccine antigen.
- He argues that the endogenous immune system can customize antibodies to a pathogen, whereas vaccines can be hyperselective and therefore more vulnerable to viral mutation and immune evasion.
- A phase-one safety study enrolled 90 people and reported no adverse events, which Stamets contrasts with the more typical phase-one sample of six or 12.
- A separate COVID-19 trial recruited 50 sick, unvaccinated participants and used mushroom mycelium without vaccine. Two of three analytical methods reached statistical significance, while the third was described as underpowered.
- Significant analyses showed large reductions across the ten principal symptoms, including headaches, muscle aches, sneezing, and coughing; coughing reductions were presented as potentially reducing droplet dispersal.
- Unvaccinated participants reportedly experienced a 50% symptom reduction 5.1 days sooner than placebo, while vaccinated participants improved 0.9 days sooner than placebo. Tamiflu was described as shortening the symptomatic period by only about one day.
- Stamets says the studies separated vaccine reactogenicity from immunogenicity, a combination he calls nearly an oxymoron in medicine, and compares the uncertainty around mechanism with aspirin, whose mechanism was not understood until the 1970s despite long clinical use.
Hormesis, Gene Expression, and Biological Response Modifiers
Huberman asks whether a small immune-priming dose might work like a nonlethal dose of poison, invoking hormesis. Stamets instead points to exercise and stresses the broader idea of biological response modifiers that alter how cells react to inflammatory challenges.
- Stamets compares the proposed immune response to the temporary inflammation produced by exercise, arguing that such hormetic stressors can help the body resist later infection.
- Published work combined lion’s mane, mushroom mycelium, turkey tail, and agaricon with lipopolysaccharide, or LPS, a bacterial endotoxin widely used to stimulate inflammation in laboratory studies.
- The fungi changed human-cell genetic responses so that they dampened inflammation that would otherwise have been intensified under stressful conditions.
- More than 500 differentially expressed genes—both up- and downregulated—were observed in human peripheral blood mononuclear cells exposed to agaricon in petri dishes.
- Stamets says the laboratory maintains 130 agaricon strains in culture, approximately 100 times more than are found in old-growth forests, and uses a $2.6 million grant to build a genomic library for identifying highly active strains.
- The strain search is compared with Mary Hunt’s discovery of a moldy cantaloupe in Peoria, Illinois, that produced 200 times more penicillin than previously known samples even though Alexander Fleming had already discovered penicillin.
- In bioassay fractionation, the agaricon team reportedly identified ibukoric acid, sulfuric acid, and furuic acid as molecules active against smallpox; none reproduced the activity of the complete fraction when tested individually.
- Stamets defines bioassay fractionation as separating a natural product into polar and nonpolar fractions—using water and hexane as examples—and then following a decision tree toward testing individual molecules.
- He argues that the immune system behaves like a sophisticated “computer of natural intelligence,” with receptor cross-talk and an entourage effect that may not be reproduced by one isolated compound.
Vaccination Hesitancy and Fungi as “Force Amplifiers”
The conversation moves from whether fungal products work to how they might fit into a population that is hesitant about vaccines. Stamets uses the “force amplifier” concept to argue that increasing efficacy and reducing side effects could influence uptake even among people with different attitudes toward vaccination.
- Huberman cites a survey in which 30% of Americans did not receive a COVID-19 vaccine because they feared adverse effects such as headaches, insomnia, or lost work and school days.
- He also notes that vaccines had saved hundreds of millions of lives, separating concerns about reactogenicity from opposition to vaccination itself.
- Stamets divides viewers into roughly three camps: those wanting greater vaccine efficacy, those wanting fewer vaccine side effects, and people opposed to vaccination. He argues that all three groups could benefit from better immune-readiness tools.
- Huberman invokes former guest Chris McCarty, a Florida professor studying plant compounds in whole-plant form, and emphasizes that many pharmaceuticals began as bioprospected natural products rather than wholly synthetic inventions.
- Stamets describes products from Moderna and Pfizer as “force amplifiers,” framing health and disease as multifactorial equations with coefficient multipliers on each side.
- In this formulation, mushroom mycelium is a force amplifier on the health side, while the vaccine supplies a targeted antigenic signal.
- Huberman argues that synergistic “cocktails” of compounds are increasingly viewed as valuable because no single government, pharmacy, or molecule can solve the full range of mental and physical health problems.
Host Defense Sourcing, Cultivation, and Personal Dosing
Stamets distinguishes cultivated mycelium from fruiting bodies and explains why sourcing and laboratory controls matter to him. He also describes his personal regimen while emphasizing that he is reporting his own practice rather than making a medical recommendation.
- Host Defense mushrooms are cultivated in Stamets’s company’s FDA-inspected laboratories, which he says have never received a Form 483.
- Production begins with tissue cultures taken from wild fungi and continues through in-vitro propagation, with the mycelium cultivated especially on grains.
- Turkey tail, Trametes versicolor, is a multicolored bracket fungus named for turkey feathers; it sequesters nitrogen by aggregating bacteria and is therefore a polyculture.
- Turkey-tail fruiting bodies are readily parasitized by bacteria, rot quickly, and can collect airborne pollution, which is part of Stamets’s preference for cultivated mycelium.
- Stamets says his greatest sourcing concern is fungi from China, and he rejects the widespread belief that Chinese mushrooms are necessarily “clean and pure.”
- Rice is used as a biological control in the trials rather than as inert filler. He compares fermenting rice with mycelium to adding bacteria to milk to produce yogurt.
- He personally takes four capsules each of the agaricon and turkey-tail products, the same materials used in the clinical studies.
- Living on a remote island in British Columbia, Stamets says he increases innate immune readiness several days before and during public exposure, then reduces the dose afterward.
- Therapeutic and maintenance doses can differ by roughly fourfold, and he says he cannot make medical recommendations; his final instruction is for listeners to follow the science.
Research Team, Funding, and the Value of Skeptics
The episode discusses the practical constraints of conducting rigorous research on complex natural products. Stamets credits skeptical collaborators for requiring publication-quality evidence and presents his own commercial work as a way to continue studies that conventional funding did not support.
- Stamets’s team includes six full-time researchers, four of whom hold PhDs, and the group has published about 65 peer-reviewed articles.
- The website mushroomreferences.com catalogs more than 1,000 references on mushroom mycelium, fruiting bodies, and adverse reactions.
- Reported adverse effects include shiitake dermatitis, in which some people develop an allergic skin reaction after merely touching shiitake mushrooms.
- Stamets applied to ten NIH grants and received two awards before founding his company and nutritional-supplement line after other funding attempts failed.
- Huberman, who has held NIH grants and served on NIH review boards for more than a decade, argues that adequate funding is necessary but not sufficient to ensure sound science.
- Stamets uses Galileo as an analogy for evidence moving from hypothesis to theory to actionable solution, noting that the Vatican later acknowledged the Church’s error in opposing Galileo.
- Huberman cites The Prince of Medicine, a history centered on Galen, and observes that ancient surgeons could operate on gladiators because those fighters were already cut open by one another.
- Stamets says his strongest supporters have often been skeptics who demanded peer-reviewed papers, double-blind studies, and placebo-controlled trials.
- He argues that continued rejection of studies meeting those standards reflects scientific bias against natural products, while Huberman continues to challenge the proposed mechanisms and ask where the proof and logic lie.
Biosecurity, AI-Engineered Bioweapons, and the Honeybee “Apocalypse”
Fungal research is placed within the broader threat of engineered pathogens and ecological collapse. Stamets argues that biodiversity and fungal products could function as forms of biosecurity, using honeybee disease as the principal example.
- Stamets says leading AI-platform figures had recently warned that bioweapons engineered by AI could become the largest threat to human extinction.
- He characterizes the bioterrorist pathway as inexpensive and capable of producing a targeted viral pandemic.
- Biodiversity is described as a form of biosecurity because functioning ecosystems provide the equivalent of the rivets holding an airplane together.
- Factory farming, dense transportation networks, and growing human populations create additional opportunities for viruses to move among animals and enter new hosts.
- Stamets says multiple viruses can incubate together in one host, enabling horizontal gene transfer, with growing bacterial populations potentially serving as a platform for that process.
- In a Nature publication involving Washington State University, Stamets’s colleagues, employees, and USDA virologist Jay Evans, mushroom extracts in sugar water reduced deformed wing virus in honeybees by as much as 14,000-fold within ten days.
- Treated bees had weakened, deformed wings and flew for about four days rather than the usual seven to ten, revealing that viral suppression did not eliminate the treatment’s biological costs.
- With one bee pollinating roughly 1,000 flowers per day, Stamets estimates that reduced bee activity could mean approximately 4,000–5,000 fewer almonds, cherries, and apples produced.
- He calls the situation a “bee apocalypse” and says his group met with the FDA in an effort to gain approval, while claiming regulators did not want to hear about viruses.
Psilocybin Evidence, Benefits, and Safety
The psilocybin discussion distinguishes large therapeutic experiences from microdosing and emphasizes both the reported antidepressant potential and the need for screening. Stamets repeatedly characterizes psilocybin as serious medicine rather than a recreational novelty.
- A survey cited in the episode found that 2.5% of Americans had used psilocybin during the previous year, including both microdosing and macrodosing; Huberman calculates this as more than eight million people.
- Roughly 70% of people are said to have a positive psilocybin experience, while COMPASS studies reportedly showed about 40–45% resolution of treatment-resistant depression or major depressive disorder.
- Depression and PTSD trials, together with observational evidence, are presented as showing increased neuroplasticity and the formation of new neural networks.
- Stamets recommends pre-screening people with a genetic, familial, or other predisposition to psychosis or bipolar disorder and says adults should be present.
- He calls psilocybin the anti-addictive drug, citing applications for opioid use disorder, tobacco, alcoholism, and obsessive-compulsive disorder.
- One frequently proposed mechanism is that dendritic spines grow from axon tips, adjacent axons make contact, and synaptogenesis establishes a new pathway that can interrupt entrenched addictive behavioral patterns.
- The “oceanic” state—ego dissolution and a sense of connection with nature or the universe—is described as a strong predictor of PTSD and depression resolution, with people who do not experience it appearing to receive less benefit.
- Stamets acknowledges that psilocybin does not work for everyone and emphasizes screening, intention, and therapeutic support as necessary components of use.
Schedule I Status, Heroic Doses, and the Griffith Follow-Up
The legal barriers surrounding psilocybin contrast with the severity and potential duration of the experiences described in the research. Stamets distinguishes informal possession changes from actual federal rescheduling and emphasizes set, setting, and aftercare.
- Psilocybin remains federally illegal to possess or sell in the United States and is classified as a Schedule I substance.
- Transporting it across state lines is described as “very federally illegal,” even in jurisdictions where local possession has been decriminalized.
- Oregon and Colorado decriminalized possession, while city councils in places including Olympia, Seattle, Mount Vernon, and Port Townsend reportedly made possession the lowest priority for law enforcement without formally legalizing it.
- The Canadian government permits psilocybin for end-of-life patients on a case-by-case basis.
- Stamets defines a “heroic dose” using the golden teacher mushroom, often at more than 2.5 grams, with the full “hero’s journey” generally described as 4–5 grams.
- He stresses that set and setting, along with therapy before, during, and after dosing, are integral rather than optional.
- A retrospective Johns Hopkins study led by the late Roland Griffith interviewed participants 14 months after heroic doses. About 70% ranked the experience among the five most positive events of their lives, while 30% described it as difficult.
- The difficult experiences were not reported as producing lasting adverse effects; some participants simply said they would not repeat them, and revisiting the memory was itself considered psychologically beneficial.
- Other observational studies cited in the episode associated a single psilocybin dose with reduced violent or heroic behavior in partners, and two heroic doses with 90% of participants not smoking cigarettes one year later compared with a nicotine-patch group.
Roots to Thrive and the Therapeutic Infrastructure Model
Roots to Thrive provides the episode’s most concrete model for psychedelic therapy. Its group format and long-term community structure are contrasted with isolated drug administration and unsupported market expansion.
- Roots to Thrive is a Canadian nonprofit co-founded by Dr. Pamela Krisco that has provided end-of-life psychedelic therapy under the government’s case-by-case permission system.
- The model uses group therapy with six to eight participants and began with end-of-life anxiety, typically among stage-four cancer patients.
- It has since expanded to uses far beyond terminal illness, including depression, addiction, and other mental-health concerns.
- Participants build a community before the experience and continue friendships and collaborative relationships afterward.
- Some participants later become sources of support for their own families, reassuring relatives who had been frightened by the prospect of death.
- The episode notes that many people who benefit from the program are not themselves dying.
- Stamets contrasts this community-based approach with selling an unguided dose as a quick commodity, arguing that infrastructure and long-term follow-up are necessary for responsible psychedelic care.
Rescheduling, Access, and Regulatory Models
Stamets and Huberman discuss what a rational transition from prohibition would look like, including clinical infrastructure, pharmacy identification, and broader access. The discussion remains aspirational: none of the three highlighted psychedelic approaches has yet completed the full FDA approval process.
- Ibogaine and psilocybin are described as moving faster than MDMA, although MDMA is a non-psychedelic empathogen rather than a classic psychedelic.
- Stamets predicts that by 2027, at least one of ibogaine, psilocybin, or MDMA will have been rescheduled to Schedule II, III, or IV.
- The policy push is portrayed as a bipartisan alliance between Rick Doblin of the MAPS Initiative and Rick Perry, the former Republican governor of Texas.
- Stamets and Huberman argue that psilocybin mushrooms should be freely available, citing a favorable cost-benefit ratio from reduced depression, addiction, violence, crime, and court involvement.
- One participant notes that his sister would never take a mushroom but would take an FDA-approved pharmaceutical, leading to the position that both forms should be available.
- There were 306 psilocybin trials registered on clinicaltrials.gov at the time of the conversation, each required to pass institutional review-board safety standards and supported by preclinical animal or in-vitro work.
- At least 20 trials use niacin as an active placebo because its flushing effect begins within about 20 minutes, creating a more visible placebo response than an inert pill.
- Stamets proposes a week-long therapeutic program with dosing, preparation, and follow-up, arguing that four to five hours of dosing can change the remainder of a person’s life.
- In Europe, pharmacists are trained to identify mushrooms, and people in Germany can bring mushrooms to a pharmacy for identification even though psilocybin itself remains illegal.
- Stamets says failure to build sensible regulation and program infrastructure would risk wasting psilocybin’s potential, concluding that “we don’t want to fumble the ball on this.”
Regulatory Barriers for Whole Natural Products
The discussion broadens the regulatory critique beyond psilocybin to fungi and other multi-constituent natural products. The contrast is between pharmaceutical purity standards and biological materials that cannot be reduced to a single predictable molecule.
- Huberman recounts a video meeting with an FDA regulator who demanded characterization of every constituent in a natural product; when told that the material contained more than 200,000 constituents, the regulator reportedly remained silent for about 45 seconds.
- Huberman contrasts that model with pharmaceuticals, which are typically 99% pure with impurities below 1%, making exhaustive impurity testing part of a workable regulatory framework for single molecules but far more difficult for whole organisms.
- The discussion says European authorities have restricted selling agaricon and turkey-tail mycelium as novel foods, limiting access to products promoted for pandemic defense even though mushrooms are themselves composed of mycelium.
- Stamets and Huberman also argue that scientific acceptance can lag practical benefit, citing meditation, breath work, yoga, and resistance training as practices that moved from fringe status to mainstream use as NIH-funded research accumulated.
- The contrast supports the episode’s broader view that regulatory categories and prevailing scientific culture can lag behind evidence or longstanding practice.
Directed Plasticity and the Limits of Psychedelic Therapy
Huberman reframes psilocybin as a tool for directed neuroplasticity rather than an indiscriminate generator of novelty. He and Stamets agree that the psychological content of a session may matter as much as its neurochemistry, even though the field has not standardized that component.
- “Directed plasticity” means using psilocybin’s capacity to create new neuronal connections to address depression, obsessions, and ruminations rather than simply seeking unusual experiences.
- Huberman says it remains unclear whether neurochemistry or the content and conduct of the session drives outcomes, and no standard protocol specifies what patients should be asked during treatment.
- The field is portrayed as knowing more about dose, strain, and screening than about what constitutes good psychedelic psychotherapy.
- Stamets claims psilocybin often makes people kinder and more tolerant, while Huberman notes that social media, bots, and clickbait increasingly monetize anger and excitement.
- He argues that roughly 95% of people share broad common beliefs and that more positive states could cross political divisions, citing families affected by opioids and veterans returning with PTSD.
- Stamets connects happiness with upregulated immunity and depression with an inflammatory state and downregulated immunity, while acknowledging that no clinical trial has tested that proposed mind-over-body relationship.
Dose Conversions, the “Museum Dose,” and Natural Mushrooms
The dosing discussion works through a set of numerical conversions and then contrasts purified psilocybin with whole mushrooms. It also includes personal boundaries that shaped Stamets’s own use.
- The episode uses a simple conversion: 0.1 gram of mushrooms equals approximately 1 milligram of psilocybin, so 1 gram equals 10 milligrams, 2.5 grams equals 25 milligrams, and 5 grams equals 50 milligrams.
- One gram is described as a “liftoff dose,” 2.5 grams as where the “hero’s journey” begins, and 5 grams as the high end of that range.
- The discussion identifies 25 milligrams as the clinical-trial standard and notes that confusion arises when “25 milligrams” is compared with “2.5 grams” without explaining the roughly 1% mushroom concentration.
- Microdoses are generally sub-sensory at 1–3 milligrams for most people, although some people report effects at 10 milligrams.
- Medium dosing, around 0.5 gram or 5 milligrams, is presented as an increasingly studied “sweet spot,” while higher or macro doses are associated with the most demanding experiences.
- The “museum dose” is a small amount of purified psilocybin that can produce brief happiness, visual stimulation, and dilated pupils, with effects lasting minutes to roughly half an hour rather than a five-hour journey.
- Stories include exceptional performance by a professional dart player and by martial artists, boxers, and baseball players, but Stamets says the behavior is dangerous and that he is not advocating it.
- Activating 5-HT2A receptors is said to engage gut receptors and the vagus nerve–mitochondrial cascade, a mechanism the episode says has not yet been adequately explored.
- Psilocybin is described as a prodrug for psilocin, so 10 milligrams of psilocybin is said to correspond to 5 milligrams of psilocin, with BDNF signaling identified as another pathway for future discussion.
- About 99.9% of psilocybin use occurs through mushrooms, while only a few hundred to a few thousand people are said to have taken the purified molecule; its lineage traces to Albert Hofmann in 1958.
- A paper by Dr. Pam Krisco and colleagues involving four participants found that all four preferred mushrooms or extracts to purified psilocybin, describing the molecule as a chemically abrupt liftoff and descent and mushrooms as having a delayed onset and longer tail.
- Diet, strain, and preparation are said to affect sensitivity, creating a tension between standardization and the entourage effect of whole mushrooms.
Alexander Smith, Family Caution, and Personal Boundaries
Personal accounts clarify that Stamets’s advocacy does not extend to recommending psilocybin to every individual. He describes declining two significant opportunities immediately before a journey.
- Alexander Smith, described as the father of American mycology, wrote a monograph on Psilocybe and studied the mushrooms throughout his life but had never eaten them.
- In his seventies, Smith asked Stamets to take psilocybin with him.
- Stamets declined Smith and his own father, approximately 74 years old and a Nixon-era opponent of recreational drug use, on the same day before leaving.
- The stated reason was that both men’s wives did not intend to take psilocybin, and Stamets did not want one spouse to have the profoundest experience of her life while the other felt excluded or unable to understand it.
- The stories underline the importance of set and setting and show that the episode’s advocacy for broader access still depends on careful screening and interpersonal context.
Microdosing Research and the Stammett Stack
The microdosing portion relies largely on observational self-report data, and both the findings and their methodological limitations are presented directly. The proposed Stammett Stack combines psilocybin, niacin, and lion’s mane around a blood-flow mechanism.
- The British Columbia citizen-science study enrolled as many as 25,000 participants and produced two observational papers in Nature Scientific Reports.
- Roughly 4,500 non-microdosers were compared with a few hundred fewer microdosers, with baseline data, motivation, dose, and combination practices recorded.
- Significant self-reported improvements were reported for depression, PTSD, and anxiety.
- Critics argued that expectation and placebo could explain the results. Stamets responded that every medicine carries an expectancy coefficient and that placebo and nocebo effects are clinically real.
- The “Stammett Stack,” named after its inventor to prevent others from taking credit, combines psilocin or psilocybin, flushing niacin, and lion’s mane mycelium.
- The proposed mechanism is that psilocin acts as a vasoconstrictor while flushing niacin, or vitamin B3, acts as a vasodilator, potentially counteracting blood-flow problems that can contribute to peripheral neuropathy.
- A ten-second psychomotor tapping test showed the stack users’ tapping frequency rising from 43 to 63 over 30 days, while non-microdosers did not show the same change.
- Participants used doses ranging from one-tenth to one-third of a gram of psilocybin.
- Stamets now describes niacin as the stack’s “force multiplier,” arguing that improved blood flow supports dendritic-spine formation, while lion’s mane contributes a separate neuroregenerative dimension.
Cordyceps, Lion’s Mane, and Reishi
The functional-mushroom section stresses species identification, cumulative rather than acute effects, and the economics that constrain natural-product research. Cordyceps receives particular attention because its commercial and scientific taxonomy can be inconsistent.
- DNA amplification of a Cordyceps sinensis fruiting body collected in the Himalayas revealed five fungal species living in the stroma, including C. sinensis, Heriotula sinensis, and a Pacil species.
- The same tissue-culture method used for oyster mushroom, shiitake, and agaricon can therefore produce a different fungus from the one on the original label.
- Cordyceps militaris is easier to grow, but confusion over which organism is actually present complicates comparisons across the C. sinensis literature.
- One study cited by Stamets involved about 73 people taking C. militaris. After two to three weeks of preparation, participants showed increases in nitric oxide, oxygen uptake, and performance ability.
- He says he cannot speak to the best time of day to take Cordyceps and does not believe its effect occurs acutely enough to support an hour-before-activity strategy.
- Lion’s mane is presented differently because its proposed neuro-stimulatory effect requires cells to divide; Stamets therefore recommends titrating medium doses rather than taking a heroic dose.
- Reishi is associated in the discussion with improved sleep quality, providing another example of an effect that unfolds over time rather than as an immediate stimulant response.
- Phase-one safety studies for Cordyceps are estimated at $1.5–2 million each, while phase-two efficacy studies can run from $5 million to $20 million.
- Stamets attributes the scarcity of trials to economics and weak intellectual-property protection rather than necessarily to lack of effect, citing artemisinin from Artemisia annua as a natural product that did complete the necessary research pathway.
- Huberman notes that many people expect an acute cognitive enhancement from Cordyceps; Stamets says continuous use may instead upregulate brain-derived neurotrophic factor, and he directs listeners to mushroomreferences.com for the underlying papers.
Mycelium as an Externalized Neural Network
Stamets and the episode’s cited work by Peter McCoy describe fungal signaling as something more organized than random chemical exchange. The proposed implications range from mycelium-derived interfaces for clothing to a much larger claim about communication across living systems.
- Mycelium is said to communicate through roughly 50 distinct chemical “word packets” and their combinations, with algorithms used to estimate the number of possible signaling sentences.
- Peter McCoy, author of the 2004 book Mushroom Running: How Mushrooms Can Help Save the World, says he proposed in 2004 that mycelium would eventually function as microcomputers.
- Stamets describes mycelium as an externalized neural network, externalized lung that exchanges carbon dioxide and oxygen, and externalized stomach that digests nutrients outside the body.
- Fungal networks compete for twigs, nutrients, and territory, leading Stamets to argue that mycelial and neural systems share fundamental properties of communication and competition.
- He says he has discussed a possible mycelium-based neural interface with an owner of Clark Shoes, envisioning shoes, garments, and hats that connect people to ecosystem-scale networks.
- One proposed design uses copper mesh membranes that become more conductive when wet, potentially allowing the interface to respond to rain.
- The episode says mycelium is sensitive to each footstep because every step occurs above hundreds of miles of underground fungal network.
- Stamets proposes that humans could seek alliances with these networks and use AI as an interface to expand ecological awareness, although this remains a speculative design direction rather than an established product.
Bennu, Tryptophan, and the “Tryptamine Universe”
An asteroid-sample finding becomes the basis for one of the episode’s most expansive interpretations. The scientific observation is separated from the proposed philosophical conclusion about consciousness and mortality.
- NASA launched a probe to asteroid Bennu in 2016; it took roughly two years to arrive, spent additional time studying the asteroid, and took about two more years to return with collected dust.
- In November 2025, NASA announced that Bennu samples contained 14 essential amino acids and unexpectedly included tryptophan, a fragile amino acid not found in other returned asteroid material.
- Tryptophan is a precursor to serotonin, connecting the asteroid finding to the episode’s discussion of mood and tryptamine signaling.
- Stamets proposes that tryptophan can decarboxylate through a simple reaction releasing carbon dioxide, forming tryptamines that he describes as “happiness molecules.”
- He extrapolates from this chemistry to a “tryptamine universe” in which mycelium-like organisms and consciousness are widespread, an idea he says unifies religious traditions and eases his feelings about mortality.
- Huberman notes that Stamets has not taken DMT, making the breadth of his claims about consciousness broader than his personal psychedelic experience.
Mycoremediation: Oil, Farm Runoff, and Radioactive Particles
The final scientific section turns to fungi as environmental tools. Successful petroleum remediation is contrasted with the limitations Stamets found in attempts to address dioxins, PCBs, and plastics.
- Mycelial enzymes can break down hydrocarbons, pesticides, and even the nerve agent VX because many such compounds become vulnerable when exposed to fungal enzymes.
- Peer-reviewed studies cited in the episode show mycelial networks capturing E. coli and preventing runoff from chicken farms and cattle ranches from reaching waterways.
- In work with Battelle Laboratories, oyster mushroom mycelium reduced bunker sea oil from approximately 20,000 parts per million to 200 parts per million over 16 weeks.
- The material passed Washington State Department of Ecology tests and was approved for freeway landscaping.
- Stamets says the enzymes take polyaromatic hydrocarbons apart at the elemental level and incorporate the resulting material into fungal carbohydrates.
- He calls his own dioxin and PCB research “a disaster” because dioxins can be degraded in a starved petri-dish culture, while a well-fed organism in an ecosystem consumes more accessible food and may ignore the toxin.
- Tightly bonded polymers such as plastics remain low on mycelium’s list of preferred substrates, limiting the optimistic claim that fungi can solve every pollution problem.
- Mycelium can also bind radioactive particles into a form that is not water-soluble, immobilizing them so they do not readily enter the food chain.
- In Mycelium Running, Stamets proposed converting mushroom farms into local mycoremediation centers, pressing spent substrate into an enzyme-rich amber liquid, rehydrating it with water, and using it to grow more mycelium.
- The proposed model would treat substrate that is currently discarded as feedstock for pollution control and food production.
From Environmental Remediation to Longevity and Happiness
Stamets explains why he is redirecting money and attention away from further remediation work. His preferred goals are individual optimization, kindness, and intergenerational benefits rather than another round of large environmental projects.
- He says he has already spent millions, in some cases tens of millions of dollars, collaborating with strong scientists on remediation research.
- His next priorities are optimization, longevity, making people nicer, and creating what he calls generations of happiness.
- He uses the image of “pebbles in the pond of happiness,” arguing that small positive actions reverberate into future lives.
- Stamets attributes his lack of perceived cognitive decline partly to using mushrooms as neuro anti-inflammatories.
- He argues that excitement about science breeds creativity and conversation, upregulates immunity, and has anti-inflammatory effects.
- His conclusion is that happiness is ultimately the strongest anti-inflammatory drug, while acknowledging that the immune connection has not been established through a dedicated clinical trial.
- He proposes that body receptors are already in continuous cross-talk, providing the biological basis for reimagining the human species without waiting for entirely new technologies.
- Huberman remarks that Stamets’s movement between galaxy-scale abstractions and highly reductionist details has helped drive progress in mycology, calling him an “N of one.”
Push-Ups, Humility, and the Seven-Generations Legacy
The closing story returns to Stamets’s twin rivalry and athletic identity before ending with a philosophy of scientific engagement. The episode closes on longevity, responsibility to descendants, and the idea that questioning authority should be done respectfully rather than cynically.
- Stamets reports doing 95 push-ups on the morning of the conversation, stating that he was 71, took no prescription drugs, and felt as though he were 35.
- He and North began competing in push-ups around age 10, using the rivalry to develop a single-set technique that continues into his later life.
- As a ninth grader in Columbiana, Ohio, he won a contest open to grades 9–12; his coach stopped him after 20 seconds when he had already completed roughly 30–40 repetitions.
- Because the rule required his nose to touch the basketball-court floor, he developed a bloody nose but continued to approximately 67 push-ups and won.
- The record reportedly stood for about 10 years, and Stamets says his coach’s intervention was the only time he stopped before completing the set.
- He cites a Harvard study in which men able to perform 40 push-ups three times per week had a 97% reduction in their potential for cardiac arrest.
- Stamets says the same figure may translate to women with a different repetition threshold and explicitly invites listeners to verify the underlying claim.
- His current method uses one set and avoids elbow hyperextension; he breaks at roughly 90 degrees because he knows from later soreness when he has pushed beyond that range.
- He urges listeners to be creative, understand why someone believes something before criticizing them, and never accept a claim as fact without asking why.
- The questioning should be done with humility, respect, kindness, and engagement, which he says is how bridges are built rather than merely how conflicts are provoked.
- He endorses the Indigenous “seven generations” concept and argues that people have a duty to descendants, even when the results of current work cannot be completed within one lifetime.
- Huberman closes by saying he and many others are grateful for Stamets’s work, while also noting that the guest’s DMT curiosity and the scientific claims about “tryptamines in the universe” remain outside what Stamets has personally tested.
![[@hubermanlab] Summarizer](https://summaries.pages.dev/img/logo.webp)
